Description of the Clinical Outcomes of Hospitalized Patients With Heart Failure With Different Serum Potassium Levels (SPLENDID)

AstraZeneca

Status: Completed

Conditions: Hyperkalemia; Hypokalemia; Heart Failure

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT05184998

D9484R00002

Details and patient eligibility

About

China National Heart Failure Registration Study (CN-HF) is a nationwide, hospital-based, multicentre, prospective registry study sponsored by Ministry of Science and Technology of the People's Republic of China. It is aimed to understand the etiology, clinical features and treatments of in-hospital HF patients in China [3].

At present, there are few studies to describe the clinical outcomes of HF patients with different sK levels in China. Utilizing the CN-HF database, this study is aimed to describe the sK levels of hospitalized HF patients and its impact to the clinical outcomes of patients.

Full description

Blood potassium disorders are a common phenomenon in patients with HF, which may be related to complications of HF (such as decreased potassium intake, renal insufficiency) and medical treatment of HF (such as diuretics, ACEi/ ARB) [9]. It is showed that abnormal changes in sK can cause myocardial cell membrane potential instability, increase the risk of malignant arrhythmia, and result in a high mortality rate [10].

Current guidelines in China recommend ACEi/ARBs, β receptor blockers, MRAs, and diuretics for treating HF patients . However, β receptor blockers, ACEi/ARB and MRA can also cause hyperkalemia , which often leads to dose reduction or even discontinuation of the medicines, it affects the patients to benefit from these treatment.

At present, there are few studies to describe the clinical outcomes of HF patients with different sK levels in China. Utilizing the CN-HF database, this study is aimed to describe the sK levels of hospitalized HF patients and its impact to the clinical outcomes of patients.

Enrollment: 6,950 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• HF patients with sK measurements on admission of hospitalization in CN-HF database will be included in this study.

Exclusion criteria

• not available for this study

Trial design

6,950 participants in 3 patient groups

Hypokalemia group

Description:

defined as sK range (0, 3.5\] mmo/L

Normokalemia group

Description:

defined as sK range (3.5, 5.0\] mmo/L

Hyperkalemia group

Description:

defined as sK range (5.0, \~) mmo/L